Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07480603

Pilot Study on a New Self Adjustable Glaucoma Drainage Device

A new self-adjustable glaucoma drainage device has been developed. And to test its efficacy and its safety, a pilot study is designed.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

SwissVisio

Sali, Senegal

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women aged 18 to 90 years.

Diagnosis of primary open-angle glaucoma meeting the following criteria:

  • Intraocular pressure (IOP) not controlled by at least one (1) or more classes of topical IOP-lowering medications, and
  • Eye without visual acuity.

Patients must be able to understand the study requirements and provide written informed consent.

Patients must be willing to follow study instructions, agree to comply with all study procedures, and be able to attend all scheduled follow-up visits for at least 6 months after surgery.

Exclusion criteria

  • Previous filtering surgery, secondary glaucoma, severe systemic disease, pregnancy, breastfeeding, or inability to understand or provide informed consent.

Pregnant or breastfeeding women, or women of childbearing potential who are not willing to use a medically acceptable method of contraception from the screening visit until the 12-month follow-up visit.

Known or suspected allergy or hypersensitivity to any component of the device (e.g., silicone).

Current participation, or participation within the last 30 days (from the screening visit), in another investigational drug or interventional device clinical trial.

Treatment and study plan

eyeValve

Device

Implantation of a self adjustable glaucoma drainage device

Primary outcomes

  1. Safety

    Time frame: 3 months

    Type and rate of complications post-surgery

  2. IOP reduction

    Time frame: Baseline versus every visit, up to 1 year

    IOP reduction by >20%

Sponsors and collaborators

Lead sponsor

Rheon Medical SA

Industry

Registry information

Official study title

Pilot Study eyeValve

Acronym: eV-SEN

Important dates

Study start
2025
Primary completion
2025
Study completion
2026
First posted
Mar 18, 2026
Registry last updated
Mar 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.